Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients:

Jaap Jan Zwaginga, MD, PhD, Ronnie van der Holt, PhD, Bart J. Biemond, MD, PhD, Peter A.W. te Boekhorst, MD, PhD, Mark Levin, MD, PhD, Art Vreughdenhil, MD, PhD, P.C. Huijgens, MD, PhD, Anneke Brand, MD, PhD, Rene van der Griend, MD, PhD, Marleen Luten, Hans Pruijt, MD, PhD, Okke de Weerdt, Elisabeth van Pampus, MD, PhD, Sonja Zweegman, MD, PhD, Rene Hollestein, Harry R. Koene, MD, PhD

Blood (2010) 116 (21): 2514.

https://doi.org/10.1182/blood.V116.21.2514.2514

Published: 2010

Journal Articles

Cost-Effectiveness of Rituximab for Maintenance in Patients with Follicular Non-Hodgkin’s Lymphoma in the Dutch Setting

Marjolein Pompen, PhD, P.C. Huijgens, MD, PhD

Blood (2008) 112 (11): 2364.

https://doi.org/10.1182/blood.V112.11.2364.2364

Published: 2008

Journal Articles

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Pieter Sonneveld, MD, Wim van Putten, MsC, Douwe Biesma, MD, Harald Holte, MD, Marinus van Marwijk Kooij, MD, Mark Henri H. Kramer, MD, P.W. Wijermans, MD, Monique Steijaert, Gustaaf W. van Imhoff, MD, P.J. Lugtenburg, MD, P.C. Huijgens, MD, Mikael Eriksson, MD

Blood (2006) 108 (11): 210.

https://doi.org/10.1182/blood.V108.11.210.210

Published: 2006

Journal Articles

Rituximab (Mabthera) Improves the Treatment Results of DHAP-VIM-DHAP and ASCT in Relapsed/Progressive Aggressive CD20 + NHL. A Prospective Randomized HOVON Trial.

Edo Vellenga, MD, PhD, Annelise Notenboom, PhD, Mars van ‘t Veer, MDPhD, Josée Zijlstra, MD, Willem E. Fibbe, MDPhD, Rien van Oers, MDPhD, Gustaaf W. van Imhoff, MDPhD, Elly Lugtenburg, MDPhD, P.C. Huijgens, MDPhD

Blood (2006) 108 (11): 328.

https://doi.org/10.1182/blood.V108.11.328.328

Published: 2006

Journal Articles

Fludarabin/Cyclophosphamide Reduced Intensity Conditioning for Allografting Offers an Excellent Outcome for Heavily Pretreated Lymphoma Patients.

A. Roel Jonkhoff, MD, PhD, J.J.W.M Janssen, MD, O. Visser, MD, H.M. van Roessel, P.C. Huijgens, MD, PhD

Blood (2006) 108 (11): 5349.

https://doi.org/10.1182/blood.V108.11.5349.5349

Published: 2006

Journal Articles

Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.

Bart W. Schot, MD, Josée Zijlstra, MD, Otto S. Hoekstra, MDPhD, Jan Pruim, MDPhD, Gustaaf W. van Imhoff, MD, Wim Sluiter, PhD, John M.M. Raemaekers, MDPhD, Wim Oyen, MDPhD, Michel Van Gelder, MDPhD, Olga Eriks, PhD, P.C. Huijgens, MDPhD, Edo Vellenga, MDPhD

Blood (2006) 108 (11): 2400.

https://doi.org/10.1182/blood.V108.11.2400.2400

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients:

Cost-Effectiveness of Rituximab for Maintenance in Patients with Follicular Non-Hodgkin’s Lymphoma in the Dutch Setting

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Rituximab (Mabthera) Improves the Treatment Results of DHAP-VIM-DHAP and ASCT in Relapsed/Progressive Aggressive CD20 + NHL. A Prospective Randomized HOVON Trial.

Fludarabin/Cyclophosphamide Reduced Intensity Conditioning for Allografting Offers an Excellent Outcome for Heavily Pretreated Lymphoma Patients.

Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients:

Cost-Effectiveness of Rituximab for Maintenance in Patients with Follicular Non-Hodgkin’s Lymphoma in the Dutch Setting

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Rituximab (Mabthera) Improves the Treatment Results of DHAP-VIM-DHAP and ASCT in Relapsed/Progressive Aggressive CD20 + NHL. A Prospective Randomized HOVON Trial.

Fludarabin/Cyclophosphamide Reduced Intensity Conditioning for Allografting Offers an Excellent Outcome for Heavily Pretreated Lymphoma Patients.

Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only